This study uses a radiologic test called PET/CT scan to determine treatment after initial doses of a standard chemotherapy called "R-CHOP" (the drugs doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab). Although all of the agents used in this study are FDA approved, the purpose of the study is to give more intensive treatment to subjects whose PET/CT scan shows that they are at a greater chance of still having active lymphoma, and to give less intensive treatment to patients whose PET/CT scan shows that they have a smaller chance of still having active lymphoma. In this way, we hope to improve the cure rate for all patients while decreasing the side effects of the treatment.
This study is for subjects with hepatocellular carcinoma (HCC) that has come back despite treatment with sorafenib. The study drug that will be used in this study, SGI-110 is investigational. This means it has not been approved for use by the FDA. The purpose of the study is to evaluate the safety, tolerability and effectiveness of SGI-110 and any potential benefits in subjects with HCC who progressed after treatment with sorafenib. Subjects are expected to be enrolled in this study for approximately 2 years.
Subjects are being asked to take part because they have clear cell renal cancer that has spread to other organs in their body. Renal cell carcinoma is the cancer that develops in the kidneys.
The purpose of this study is to test a new cancer treatment drug called BNC105P in combination with everolimus to see what effects (good and bad) it has on subjcets and their cancer. BNC105P is a drug that causes changes in the lining of the blood vessels nourishing the tumor cells more than the lining of the blood vessels nourishing the normal cells. These changes in the lining of the blood vessels reduces blood flow to the tumor causing reduced blood supply/nourishment to the tumor resulting in death of the tumor cells and reduction of the tumor size.
This study will be done in 2 parts; Phase I and Phase II.
The purpose of the Phase I part of the study is to:
• test the safety of BNC105P (a new type of drug used to treat cancer) when given together with Everolimus
• find the highest dose of BNC105P that can be given together with Everolimus without causing severe side effects
• see what effects (good and bad) BNC105P has on you and your cancer
The purpose of the Phase II part of the study is to:
• Evaluate if adding BNC105P to the Everolimus is better than Everolimus treatment when given alone and see what effect (good or bad) BNC105P will have when given following Everolimus treatment.
Subjects will have screening procedures to determine if he or she is eligible to participate in this study. If he or she is eligible and agrees to participate, subjects will either participate in Phase I or Phase II. Subjects in Phase I will receive EVEROLIMUS at 10 mg by mouth daily and BNC105P by IV.
If subjects are in the Phase II portion of the study, they will be randomized in to either Group A or Group B. Group A subjects will also receive EVEROLIMUS at 10 mg by the mouth daily and BNC105P by IV. Subjects in Group B will receieve EVEROLIMUS at 10 mg by mouth daily only.
Subjects will be followed by study team members for the rest of their lives to look at the long term effects of the study treatment.
Subjects will be asked to volunteer to participate in a research study of study drug known as LY2784544 because they have Myelofibrosis.
Subjects in Group 1, will receive LY2784544, capsule or tablet, by mouth 2 times a week. They will also receive a co-medication (allopurinol or an appropriate substitute) which will be administered by mouth once a day starting the day before the first dose of LY2784544.
Subjects in Group 2 will receive LY2784544, capsule or tablet, by mouth 3 times a week. They will also receive a co-medication (allopurinol or an appropriate substitute) which will be administered by mouth once a day starting the day before the first dose of LY2784544.
Both groups: After completing a 28-day cycle dosing regimen as per above (Group 1 or Group 2), they will be evaluated for eligibility to transition to daily dosing. Allopurinol may be given as a co-medication and this will be determined by the study doctor.
Stored blood (DNA/RNA/circulating biomarkers) and bone marrow collection are a required part of this study. Genetic testing is also a mandatory part of this study.
Subjects will be in this study for approximately 6 months or until disease progression with a 30-day follow-up period
The purpose of this research study is to find what effects (good and bad) ArginMax has on erectile dysfunction in prostate cancer survivors treated with radiotherapy.
ArginMax is a dietary supplement that contains extracts of L-arginine, ginseng, ginkgo biloba, multivitamins, and minerals and has been taken for erectile dysfunction. This supplement is not approved by the Food and Drug Administration (FDA).
In this study, participants will receive a low or high dose of the study medication given twice a day. Active drug will be compared to a placebo also taken twice a day.
The purpose of this study is to understand if small proteins found on the surface of myeloma cells (called CXCR4, CD47, and beta 2 adrenergic receptors) can predict how patients will respond to chemotherapy-treatment and if a small molecule inside the myeloma cells (called Pim kinase) can be used as a treatment target for myeloma. A sample from the bone marrow biopsy (a small amount of tissue removed from the body for laboratory testing) and aspirate (a small amount of fluid is removed from the body for laboratory testing) that you had done before you entered this study will be provided for research purposes. A small amount of the patient's bone marrow samples will be sent to our research laboratory to measure the CXCR4, CD47, beta 2- adrenergic receptor and the Pim kinase on the cells. Some of the cells will be grown in the lab and tested to measure the responses to new treatment agents. The researchers will check your medical records to gather information about you are responding to treatment, your cell counts and your laboratory data. Participation in the study will include 1 visit at MUSC at the same time as you are having the bone marrow biopsy procedure. The study doctor and his research staff may reference your medical records for information for up to five years after this study visit.
This study is for patients that have been diagnosed with intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. A new compound called SAR302503 is being developed by Sanofi-Aventis as an orally available treatment for myelofibrosis (MF). This compound is a small molecule that blocks the activity of a protein called JAK2. This study aims to evaluate the efficacy of a once daily dose of SAR302503 in patients previously treated with ruxolitinib. Participants in this study will receive 400 mg of SAR302503 per day as a starting dose. After 2 cycles on the study, the doctor may increase the dose to 500 mg per day and after 4 cycles on the study; the doctor may increase the dose to 600 mg per day. Once enrolled into the study, the study will end after the first six (6) cycles of the treatment (approximately seven (7) months). However, if the patient is benefiting from treatment, he/she may be able to continue to take the study drug provided.
This study is for subjects with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has returned after treatment or did not respond to earlier treatment. The purpose of this study is to compare pegylated liposomal doxorubicin (PLD; a standard chemotherapy) to PLD in combination with VTX-2337 (a new type of drug that stimulates the immune system) to see if it helps cancer tumors stop growing or shrink, and if it helps women with these types of cancer live longer. PLD is an FDA-approved treatment for women with ovarian cancer. In prior studies, approximately 15–20% of women who received PLD for relapsed ovarian cancer experienced a temporary shrinkage or disappearance of their tumor. VTX 2337 is an experimental drug (not approved by the Food and Drug Administration, FDA) that stimulates the immune system and may help the body kill cancer cells. The combination of PLD plus VTX-2337 has been evaluated in a previous study of 13 patients. The study is still ongoing, but so far there is evidence that PLD + VTX-2337 may temporarily stop some patients’ tumors from growing (this happened in 6 patients), or it may help cancer tumors temporarily shrink and/or disappear (this happened in 1 patient).
In addition to the treatment part of this study, the researchers plan to test samples of your tumor and some of your blood. You cannot participate in this study if you do not agree to provide these specimens for this research. The purpose of this research is to examine the impact the study drugs have on tumor tissue and specific blood cells and substances.
Lastly, researchers want to know if one's genes (DNA) affect how the body responds to the experimental medication or how one's body breaks it down. Subjects will receive the study drugs as long as there is evidence that their tumor is not growing and they are not experiencing unacceptable side effects.